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Slow and incomplete reconstitution of cellular and
humoral immunity has long been recognized as a weak link
limiting the success of allogeneic hematopoietic stem cell
transplantation (allo-HSCT). Delayed posttransplantation
reconstitution of the adaptive immune system is associated
with increased infection, relapse, secondary malignancies,
and overall mortality in recipients of an allo-HSCT [1,2]. In
particular, reconstitution of the T cell compartment can take
1-2 years, and deﬁciencies in the T cell repertoire can persist
even longer. Deﬁciencies in T cell reconstitution are depen-
dent on patient age, conditioning regimen, use of in vitro or
in vivo T cell depletion to decrease graft-versus-host disease
(GVHD), HLA disparity between donor and recipient, and
GVHD prophylaxis, as well as the occurrence of GVHD. T cell
recovery after allo-HSCT occurs through 2 unrelated mech-
anisms: (1) peripheral expansion of infused donor T cells
and, to a lesser extent, residual host T cells, and (2) de novo T
cell development in the thymus. Peripheral expansion is
associated with a narrow repertoire, whereas de novo T cell
development can reconstitute a full T cell repertoire.
However, damage from conditioning and GVHD, in combi-
nation with age-associated involution, results in poor post-
transplantation thymic function. Consequently, this review
takes a “bench-to-bedside” approach, evaluating strategies
aimed at enhancing not only the peripheral expansion of the
tumor and virus-speciﬁc immune response, but also the
recovery of thymic function (Figure 1).
STRATEGIES TO ENHANCE POSTTRANSPLANTATION
THYMIC RECOVERY
Although some evidence suggests that extrathymic T cell
development can occur, the majority of T cells are generated
in the thymus. Thus, most strategies for improving post-
transplantation T cell reconstitution target the thymus. The
thymus is continuously seeded by T cell precursors origi-
nating in the bone marrow from hematopoietic stem cells.
Through a well-deﬁned process involving positive and
negative selection and signiﬁcant crosstalk between devel-
oping thymocytes and the thymic stroma, these precursors
generate a diverse pool of functional CD4 and CD8 T
lymphocytes with little or no autoreactivity. The thymic
stroma include dendritic cells, macrophages, ﬁbroblasts,
endothelial cells, and medullary and cortical thymicFinancial disclosure: See Acknowledgments on page S82.
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cell precursors into the thymus in the early stages after
transplantation and (temporary) deﬁciencies in non-
epithelial stromal cells can contribute, the loss of TECs from
involution, conditioning, and GVHD seems to be the most
important cause of poor posttransplantation thymic
function.
Several strategies aimed at enhancing post-
transplantation thymic recovery have been developed in
preclinical models, some of which are now in clinical trials:
1. IL-7 is required for normal lymphopoiesis and supports T
cell development at most stages of T cell development
and differentiation. IL-7 supports T cell precursors,
enhances thymopoiesis, and stimulates homeostatic
proliferation in the periphery, primarily through
enhanced proliferation and inhibition of apoptosis.
Clinical experience with recombinant human IL-7
(rhIL-7; CYT 99 007) demonstrated a dose-dependent
expansion of CD4þ and CD8þ T cells in patients with
solid tumors or HIV infectionwith acceptable toxicity [3].
Importantly, a phase I study with glycosylated rhIL-7
(CYT107) recently completed in patients after alloge-
neic T celledepleted HSCT showed similar results, with
expansion of CD4þ and CD8þ T cells and an increase in
CD4þ and CD8þ T cells (Perales et al., unpublished).
2. Keratinocyte growth factor (KGF) enhances thymopoi-
esis through trophic effects on TECs in preclinical models
[4]. KGF is approved for the prophylaxis of mucositis, and
clinical trials to assess its effects on posttransplantation T
cell recovery are under way.
3. Growth hormone (GH) enhances thymopoiesis and
hematopoietic stem cell function in the bonemarrow [5].
HIV-positive patients given GH demonstrate improved
thymic function and antiviral response.
4. Other cytokines and growth factors, including FMS-like
tyrosine kinase 3 ligand, insulin-like growth factor 1,
IL-2, IL-12, and IL-15, show promise based on preclinical
studies.
5. Sex steroid ablation as a strategy for enhancing post-
transplantation immune reconstitution is based on the
regulatory roles for estrogen and testosterone in B and T
lymphopoiesis in the thymus and bone marrow. Studies
in mice andman (including recipients of an auto- or allo-
HSCT) using surgical or chemical castration showed
improved thymopoiesis and peripheral T cell reconsti-
tution [6]. Clinical studies have used the LHRH analog
Leuprolide, resulting in transient chemical castration
and additional studies with Leuprolide in allo-HSCT
recipients are under way.Transplantation. Published by Elsevier Inc. All rights reserved.
Figure 1. Strategies to improve immune reconstitution after HSCT. As shown in this schema, strategies to enhance posttransplantation thymic recovery post-HSCT
include IL-7, GH, and KGF. Donor-derived virus-speciﬁc T cells can be given to rapidly restore virus-speciﬁc immunity in patients with or without active viral infection.
Tumor-speciﬁc T cells or NK cells may be given early posttransplantation to capitalize on the lymphopenic environment for enhanced expansion and persistence
in vivo to prevent relapse. Furthermore, these approaches may be coupled with tumor vaccine strategies to augment the antitumor response for treating patients
with detectable disease.
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for children with DiGeorge syndrome or other forms of
congenital thymic hypoplasia.
Additional strategies currently under exploration in
preclinical models include adoptive therapy with ex vivo
generated nonmatched “off-the-shelf” T cell precursors, cell
therapy with TECs, and artiﬁcial thymus implants. In
summary, strategies to enhance posttransplantation T cell
reconstitution have shownpromise in preclinical studies, and
several of those (in particular IL-7, KGF, sex steroid ablation,
and GH) are now being tested in allo-HSCT recipients.
VIRUS-SPECIFIC IMMUNE RECONSTITUTION
Severe, sometimes fatal viral infections are common after
HSCT, and although standard therapy includes pharmaco-
logic agents, these agents are associated with substantial
toxicities, are often ineffective, and do not provide long-term
protection. In contrast, infusion of donor-derived virus-
speciﬁc T cells has proven safe and effective.
Adoptive Transfer of Ex Vivo Expanded T Cells
The ﬁrst adoptive transfer studies were based on the
principal that donor peripheral blood contains T cells able to
mediate antiviral activity in HSCT recipients. However, given
the low frequency of virus-speciﬁc cells and relatively high
frequency of alloreactive cells, donor leukocyte infusion was
often associated with GVHD in vivo, which limited its clinical
utility. In an effort to increase efﬁcacy and reduce toxicity,
various strategies have been devised to speciﬁcally select
virus-speciﬁc cells or enrich virus-directed T cells by in vitro
stimulation and expansion.
Selection of Virus-Speciﬁc T Cells
Virus-speciﬁc T cells can be selected directly from blood
with HLA peptide multimers or by capturing virus-directed
cells secreting IFN-g in response to stimulation (g-capture).Multimer-selected CD8þ T cells were ﬁrst used to treat
cytomegalovirus (CMV) reactivation. In one study, infusion of
small numbers of cells (median, 8.6  103 cells/kg) was
sufﬁcient to mediate viral clearance in 8 of 9 treated patients
[7]. More recently, Uhlin et al. [8] moved beyond CMV and
used multimer-selected cells isolated from both frozen stem
cell donor material and third-party donors to treat CMV,
Epstein-Barr virus (EBV), and adenovirus (Adv) infections.
Within 2 weeks of infusion, they saw a decrease in viral titers
in 6 of 8 treated patients, with no GVHD [8]. Although this
approach might have utility beyond the donor-speciﬁc
setting, multimer selection is restricted to CD8þ T cells
with known epitope speciﬁcities. In contrast, g-capture
provides an HLA-unrestricted means of selecting virus-
speciﬁc polyclonal (CD4þ and CD8þ) T cells using either
peptides or whole antigen as a stimulus and infusing small
numbers of cells (w1  104/kg) has proven effective in
treating Adv [9], CMV [10], and EBV [11] infections.
Although both strategies are rapid and clinically effective,
the selection process is expensive and requires large starting
blood volumes. Thus, their use has largely been limited to
restricted cases of urgent medical need. In addition, the low
frequency of circulating cells speciﬁc for certain viruses may
limit the applicability of these approaches.
Ex Vivo Expansion of Virus-Speciﬁc T Cells
Virus-speciﬁc immune reconstitution also can be achieved
using ex vivo expanded T cells generated by repeated anti-
genic stimulation, which serves to preferentially expand cells
with the desired speciﬁcity. T cells active against CMV, EBV,
Adv, and combinations of these viruseshavebeenpreparedby
stimulating donor T cells with peptides, viral lysate, and
vector-transduced or virus-transformed antigen-presenting
cells (APCs). Postinfusion, these cells can reconstitute
immune responses against the target viruses and provide
long-term protection [12-14]. But although these ex vivo
expanded T cells have proven safe and effective in vivo,
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therapy on a broader scale. In particular, trivirus-speciﬁc T
cells directed against EBV, CMV, and Adv are generated using
monocytes and EBV-transformed B cells transduced with
a clinical-grade adenovector to stimulate Tcells over a 4- to 6-
week period in tissue cultureetreated 24-well plates [14]d
a complicated, lengthy, and labor-intensive process. More-
over, the clinical-grade vector/live virusmaterial is expensive
to make and test. To overcome these obstacles, we and
others have explored recent advances in culture practices to
develop more rapid and cost-effective strategies for T cell
production:
1. Exclusion of virus material. In an effort to develop
alternative Good Manufacturing Practiceecompliant
strategies, we substituted live virus/vector with DNA
plasmids encoding a range of immunodominant and
subdominant CMV, EBV, and Adv antigens and used
plasmid-nucleofected dendritic cells as T cell stimula-
tors. The activity of these cells is currently under clinical
evaluation. More recently, we evaluated clinical-grade
overlapping peptide libraries as alternate antigen sour-
ces and demonstrated that APCs resident in peripheral
blood are capable of processing and presenting these
peptides to virus-speciﬁc T cells. This manufacturing
modiﬁcation not only eliminates the need to create
a dedicated APC population, but also allows for large-
scale T cell production from small (<20 mL) starting
blood volumes [15].
2. Simplify production. Traditionally, the expansion of
antigen-speciﬁc T cells ex vivo has relied on culture
propagation in 2-cm2 wells of 24-well plates, which are
unsuitable for routine production of large cell numbers.
Thus, robust and scalable manufacturing techniques
must be developed before T cell therapies can become
a standard of care. To this end, we evaluated a gas-
permeable rapid expansion device (G-Rex; Wilson Wolf
Manufacturing Corporation, New Brighton, MN), which
reduces the number and duration of cell manipulations
involved in T cell line manufacturing. These ﬂasks
have remarkable linear scalability of cell growth over
the tested surface area range of 10e1000 cm2, corre-
sponding to a production of 2 108 to 2 1010 T cells per
ﬂask.
3. Broader implementation. Although many barriers have
been overcome, current techniques still require special-
ized centers to prepare “individualized” T cell products.
This limitation could be overcome if banked “off-the-
shelf” T cells, administered in the partially HLA-matched
setting, are shown to have a safety and efﬁcacy proﬁle
similar to donor-speciﬁc products. As a proof of concept,
Haque et al. [16] demonstrated that partly HLA-matched
third-party EBV-speciﬁc T cells produced clinical beneﬁt
after solid organ transplantation, and O’Reilly et al. [17]
reported similar results in the HSCT setting. In
a National Heart, Lung, and Blood Institute Production
Assistance for Cellular Therapiesesponsoredmulticenter
study, we tested whether banks of third-party trivirus T
cells could produce clinical beneﬁt in 50 HSCT recipients
with refractory infections [18]. We found an overall
response rate of >80%, even in cases when only a single
HLA antigen was matched [18]. Thus, such mismatched
products could be made rapidly available for widespread
distribution, or could serve as an interim treatment
while a patient-speciﬁc product is manufactured.In summary, improved strategies should extend T cell
therapy to a broad spectrum of clinically relevant viruses
using a single product and move adoptive T cell therapy from
a boutique application toward a standard of care.
ENHANCING IMMUNE RESPONSES TO TUMOR ANTIGENS
POSTTRANSPLANTATION
In contrast to the impressive progress made against
infectious morbidity and mortality, tumor recurrence
remains a major barrier to the success of allo-HSCT for
malignant disease. Advances in our understanding of graft-
versus-tumor effects and an ever-increasing array of
immune-based therapies has led many to believe that
immune-based therapies incorporated in the post-
transplantation setting provide the best hope for improved
outcomes. As a result, the nexus between immune reconsti-
tution and tumor recurrence has become an area of intense
study. The following questions address areas of current
interest and recent progress at the interface of immune
reconstitution and immunotherapy:
1. Does impaired immune reconstitution after HSCT
increase the risk of tumor recurrence, and does
promoting immune reconstitution diminish tumor
recurrence? The theory of immune surveillance, put
forth by Burnet in 1957, posits that endogenous immu-
nity prevents the outgrowth of some incipient cancers.
This hypothesis remained highly controversial until
careful animal studies clearly documented that immu-
nodeﬁcient animals aremore susceptible to awide array
of tumors well beyond viral-induced cancers. This work
went on to illustrate that the interface between
a growing tumor and the host immune system sculpts to
emphasize those clones with the most immune-
evasive properties, and that both adaptive immunity
[19] and innate immunity [20] can mediate immune
surveillance. The overall process has been described as
immunoediting.
The corollary to the hypothesis of immunoediting is
that tumors growing in immunodeﬁcient hosts are less
immune-evasive and more susceptible to eradication by
a healthy immune system compared with those growing
in immunocompetent hosts. This conceptual framework
leads to the prediction that cancers recurring in immu-
nodeﬁcient hosts, such as HSCT recipients, will be more
immunogenic than those found in nonimmunodeﬁcient
hosts. It further suggests that immune reconstitution
may mediate antitumor effects, and that immunothera-
peutic strategies may be more effective in an immuno-
suppressed patients than in patients whose tumors recur
in the setting of a normal immune system.
We have tested these hypotheses in patients with
high-risk pediatric solid tumors subjected to intensive
lymphodepleting chemotherapy for the treatment of
primary tumor but considered at high risk for tumor
recurrence in the lymphopenic period after completion
of standard therapy. Using a combination of adoptive
transfer of autologous lymphocytes with or without rhIL-
7 and tumor vaccines, we tested whether immune
reconstitution plus vaccination after standard therapy
can reduce tumor recurrence. Preliminary results show
impressive immunorestorative properties of rhIL-7 in
this setting with minimal toxicity. Vaccine responses are
robust, and survival in these high-risk patients appears
improved compared with a historical control group.
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regulatory T cell populations. These results suggest that
immunorestorative therapies can diminish tumor recur-
rence in high-risk patients, consistent with the immu-
noediting hypothesis.
2. Is the lymphopenic milieu the optimal setting in which
to undertake T cellebased therapies? Can the favorable
factors induced by lymphopenia be delivered in non-
lymphopenic hosts with similar or enhanced beneﬁts?
Historically, the impaired immune system induced by
allo-HSCT has been considered an abnormality in need of
correction, and investigators have emphasized the
potential enhanced susceptibility to tumor recurrence.
However, recent progress in the ﬁeld of adoptive cell
therapy has emphasized the limitations on sustaining
the expansion of tumor-speciﬁc T cells imposed by an
intact immune system. Indeed, historical animal data
and clinical results demonstrate that patients with
lymphopenia can undergo effective vaccination, and that
the relative size of the antigen-speciﬁc pool is increased
in the setting of lymphopenia. Furthermore, animal
models and nonrandomized clinical trials have demon-
strated that adoptive cell therapies are more effective
when administered to lymphopenic hosts [21]. These
effects are related in part to elevated endogenous
homeostatic cytokines induced by lymphopenia, which
enhance the effectiveness of adoptive cell therapy and
vaccine therapies [22]. Depletion of regulatory T cells
(Tregs) by lymphodepleting regimens also has been re-
ported, although the Treg depletion induced by lym-
phodepleting therapies is short-lived and associated
with a subsequent “overshoot” in Treg expansion that
potentially limits the beneﬁts of this effect [23]. Finally,
cytotoxic therapy also may enhance the effectiveness of
immunotherapy by augmenting innate immunity,
perhaps via mucosal damage and bacterial transfer with
subsequent LPS leakage into the vasculature [24].
Thus, although potential beneﬁts of lymphopenia
have been emphasized in many studies, it is also clear
that limitations in repertoire diversity and a propensity
for T cells to undergo programmed cell death during
expansion in lymphopenic hosts might limit the effec-
tiveness of immunotherapy administered in lympho-
penic hosts. In an attempt to harness the beneﬁcial
physiology of lymphopenia while avoiding the negative
effects of limited repertoire diversity and the propensity
forprogrammedcell death,we treatedTcellerepletemice
and lymphopenic mice with tumor vaccine plus immu-
notherapy with rhIL-7 and Treg depletion. We observed
improved outcomes in lymphoreplete hosts treated with
speciﬁc approaches to improve immune reconstitution
compared with lymphopenic hosts [23]. Tumor vaccina-
tion was associated with epitope spreading in immuno-
competent hosts, but not in lymphopenic hosts [23]. We
conclude that lymphopenia provides advantages over
nonprepared hosts, but that the most desirable milieu is
one created by targeted therapies (eg, homeostatic cyto-
kine plus Treg depletion) that speciﬁcally enhance
immune responsiveness but leave the immune repertoire
intact.
3. Can the profound lymphopenia present in the early days
after allo-HSCT be used to support natural killer (NK) cell
expansion in the context of adoptive cellular therapy?
Profound lymphopenia is seen in the ﬁrst few weeks
after allo-HSCT, and NK cells are usually the ﬁrstlymphocyte subset to recover. Previous studies have
shown that NK cells mediate beneﬁcial antileukemic
effects after allo-HSCT, and approaches aimed at
expanding cytolytic NK cells for adoptive cell therapy
have been developed [25-27]. Adoptive therapy with IL-
2eactivated haploidentical NK cells reportedly induces
antileukemia effects in patients with acute myelogenous
leukemia [28], and current thinking holds that NK cells
do not induce GVHD.
Thus, we have postulated that adoptive NK cell therapy
administered in the early days after allo-HSCT will exploit
the altered immunologic milieu and enhance NK expansion
and antitumor effects, with only a limited risk of GVHD.
T celledepleted peripheral blood stem cells from matched
related and matched unrelated donors were administered
after a nonmyeloablative conditioning regimen in patients
with ultra-high-risk pediatric solid tumors. 4-1BBL/IL-15
activated and expanded donor-derived NK cells were
administered on days 7 and 35 after allo-PBSCT. We
observed clinical signs and symptoms consistent with
cytokine release and GVHD in patients receiving activated
NK cells, as well as preliminary evidence for antitumor
effects. Results from this ongoing trial will be presented in
a sequel.
CONCLUSION
In conclusion, impaired immune reconstitution after allo-
HSCT can be viewed as both a friend and a foe. Some
preclinical data and emerging clinical data suggest that
impaired immune reconstitution may increase the risk of
tumor recurrence. At the same time, the altered immunology
milieu provides opportunities for inducing potent immune
responses that would not be possible in immunocompetent
hosts. Furthermore, the immunoediting hypothesis holds
that immunotherapies administered in this setting will be
more effective than those administered to immunocompe-
tent hosts. Taken together, these considerations provide
a rationale for administering directed immunotherapies after
allo-HSCT to prevent tumor recurrence. Adoptive cell
therapy using T cells and NK cells, as well as tumor vaccines,
all hold promise and could be augmented by the milieu of
this unique setting.
ACKNOWLEDGMENTS
Financial disclosure: The authors have nothing to disclose.
REFERENCES
1. Dudakov JA, van den Brink M. Strategies for immune reconstitution
following allogeneic hematopoietic cell transplantation. UpToDate.
2012. in press.
2. Holland AM, van den Brink MR. Rejuvenation of the aging T cell
compartment. Curr Opin Immunol. 2009;21:454-459.
3. Morre M, Beq S. Interleukin-7 and immune reconstitution in cancer
patients: a new paradigm for dramatically increasing overall survival.
Target Oncol. 2012;7:55-68.
4. Rossi S, Blazar BR, Farrell CL, et al. Keratinocyte growth factor preserves
normal thymopoiesis and thymic microenvironment during experi-
mental graft-versus-host disease. Blood. 2002;100:682-691.
5. Taub DD, Longo DL. Insights into thymic aging and regeneration.
Immunol Rev. 2005;205:72-93.
6. Sutherland JS, Goldberg GL, Hammett MV, et al. Activation of thymic
regeneration in mice and humans following androgen blockade.
J Immunol. 2005;175:2741-2753.
7. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of
cytomegalovirus-speciﬁc CTL to stem cell transplant patients after
selection by HLA-peptide tetramers. J Exp Med. 2005;202:379-386.
8. Uhlin M, Gertow J, Uzunel M, et al. Rapid salvage treatment with virus-
speciﬁc T cells for therapy-resistant disease. Clin Infect Dis. 2012;55:
1064-1073.
M. van Den Brink et al. / Biol Blood Marrow Transplant 19 (2013) S79eS83 S839. Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer
of virus-speciﬁc T-cell immunity for the treatment of systemic
adenovirus infection after allogeneic stem cell transplantation. Br J
Haematol. 2006;134:64-76.
10. Peggs KS, Thomson K, Samuel E, et al. Directly selected
cytomegalovirus-reactive donor T cells confer rapid and safe systemic
reconstitution of virus-speciﬁc immunity following stem cell trans-
plantation. Clin Infect Dis. 2011;52:49-57.
11. Moosmann A, Bigalke I, Tischer J, et al. Effective and long-term control
of EBV PTLD after transfer of peptide-selected T cells. Blood. 2010;115:
2960-2970.
12. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular
immunity against cytomegalovirus in recipients of allogeneic bone
marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;
333:1038-1044.
13. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modiﬁed virus-speciﬁc
T lymphocytes to control Epstein-Barr-virus-related lymphoprolifera-
tion. Lancet. 1995;345:9-13.
14. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes
speciﬁc for multiple viruses expand and produce clinically relevant
effects in immunocompromised individuals. Nat Med. 2006;12:
1160-1166.
15. Gerdemann U, Keirnan J, Katari U, et al. Rapidly generated multivirus-
speciﬁc cytotoxic T lymphocytes for the prophylaxis and treatment of
viral infections. Mol Ther. 2012;20:1622-1632.
16. Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein-Barr-virus-
positive post-transplantation lymphoproliferative disease with
partly HLA-matched allogeneic cytotoxic T cells. Lancet. 2002;360:
436-442.
17. Doubrovina E, Oﬂaz-Sozmen B, Prockop SE, et al. Adoptive immuno-
therapy with unselected or EBV-speciﬁc T cells for biopsy-proven EBVþ
lymphomas after allogeneic hematopoietic cell transplantation. Blood.
2012;119:2644-2656.
18. Leen AM, Bollard CM, Mendizabal AM, et al. Most closely HLA-matched
allogeneic virus-speciﬁc cytotoxic T-lymphocytes (CTL) to treatpersistent reactivation or infection with adenovirus, CMV and EBV
after hemopoietic stem cell transplantation (HSCT) [abstract]. Blood.
2010;116(suppl 1):829.
19. Matsushita H, Vesely MD, Koboldt DC, et al. Cancer exome analysis
reveals a T-celledependent mechanism of cancer immunoediting.
Nature. 2012;482:400-404.
20. O’Sullivan T, Saddawi-Konefka R, Vermi W, et al. Cancer immunoe-
diting by the innate immune system in the absence of adaptive
immunity. J Exp Med. 2012;209:1869-1882.
21. Wrzesinski C, Restifo NP. Less is more: lymphodepletion followed
by hematopoietic stem cell transplant augments adoptive T-cell-
based anti-tumor immunotherapy. Curr Opin Immunol. 2005;17:
195-201.
22. Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic
cytokine sinks by lymphodepletion enhances the efﬁcacy of adop-
tively transferred tumor-speciﬁc CD8þ T cells. J Exp Med. 2005;202:
907-912.
23. Cui Y, Zhang H, Meadors J, et al. Harnessing the physiology of lym-
phopenia to support adoptive immunotherapy in lymphoreplete hosts.
Blood. 2009;114:3831-3840.
24. Paulos CM, Wrzesinski C, Kaiser A, et al. Microbial translocation
augments the function of adoptively transferred self/tumor-
speciﬁc CD8þ T cells via TLR4 signaling. J Clin Invest. 2007;117:
2197-2204.
25. Vivier E, Ugolini S, Blaise D, et al. Targeting natural killer cells and
natural killer T cells in cancer. Nat Rev Immunol. 2012;12:239-252.
26. Fujisaki H, Kakuda H, Shimasaki N, et al. Expansion of highly cytotoxic
human natural killer cells for cancer cell therapy. Cancer Res. 2009;69:
4010-4017.
27. Zhang H, Cui Y, Voong N, et al. Activating signals dominate inhibitory
signals in CD137L/IL-15 activated natural killer cells. J Immunother.
2011;34:187-195.
28. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive
transfer and in vivo expansion of human haploidentical NK cells in
patients with cancer. Blood. 2005;105:3051-3057.
